| Immunotherapy shows clinical benefit in nearly half of blood cancer patients who had relapsed following allogeneic stem cell transplantation |
|
A multicenter phase 1 trial of the immune checkpoint blocker ipilimumab found clinical benefit in nearly half of blood cancer patients who had relapsed following allogeneic stem cell transplantation... Fonte: Immune System/Vaccines News From Medical News Today |